Redhill Biopharma (Redhill Biopharma) Marketable Securities : $0.02 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Redhill Biopharma's Marketable Securities for the quarter that ended in Jun. 2023 was $0.02 Mil.

Redhill Biopharma's annual Marketable Securities declined from Dec. 2021 ($8.53 Mil) to Dec. 2022 ($0.02 Mil) and declined from Dec. 2022 ($0.02 Mil) to Dec. 2023 ($0.00 Mil).

Redhill Biopharma Marketable Securities Historical Data

The historical data trend for Redhill Biopharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Marketable Securities Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

18.85

0.50

8.53

0.02

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial															0.02	0.02	0.02	0.02	-

Redhill Biopharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Redhill Biopharma (NAS:RDHL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Redhill Biopharma Marketable Securities Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.